Colosimo et al. 50M Metastatic Renal Carcinoma

by Benny | Apr 21, 2021

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Colosimo et al.50-year-old man with metastatic renal carcinoma These are representative images from reference studies;...

Colosimo et al. 52F Primary Glioma

by Benny | Apr 21, 2021

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Colosimo et al.52-year-old woman with primary glioma These are representative images from reference studies; individual...

Seidl et al. 48F with Non-Hodgkins Lymphoma

by Eric | Apr 20, 2021

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL vs. Gadavist® (gadobutrol)1 The MERIT StudySeidl et al.48-year-old woman with non-Hodgkins lymphoma These are representative images from reference studies; individual results may vary.Reference: 1. Seidl Z,...

Seidl et al. 60F with Lung Cancer

by Eric | Apr 18, 2021

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL vs. Gadavist® (gadobutrol)1 The MERIT StudySeidl et al.60-year-old woman with lung cancer These are representative images from reference studies; individual results may vary.Reference: 1. Seidl Z, Vymazal J,...

NEW: Vaneckova et al. 62F Lung Adenocarcinoma

by Eric | Apr 17, 2021

MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL vs. Dotarem® (gadoterate meglumine)1 BENEFIT studyVaneckova et al.62-year-old woman with lung adenocarcinoma These are representative images from reference studies; individual results may vary.Reference: 1....